Abstract
The hyperimmunoglobulinemia D periodic fever syndrome (HIDS) is caused by recessive mutations in the mevalonate kinase gene, which encodes an enzyme involved in cholesterol and nonsterol isoprenoid biosynthesis. The pathogenesis and treatment remains unclear. We describe a 6-year-old Turkish girl with severe disease. Her clinical features were accompanied with very high acute-phase reactants including a very high serum amyloid A level. The patient responded well to anti-tumor necrosis factor treatment. Our findings support the use of this anti-cytokine treatment in HIDS.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Houten SM, Frenkel J, Waterham HR (2003) Isoprenoid biosynthesis in hereditary periodic fever syndromes and inflammation. Cell Mol Life Sci 60(6):1118–1134
Obici L, Manno C, Muda AO et al (2004) First report of systemic reactive (AA) amyloidosis in a patient with the hyperimmunoglobulinemia D with periodic fever syndrome. Arthritis Rheum 50(9):2966–2969
Drenth JP, van der Meer JW, Kushner I (1996) Unstimulated peripheral blood mononuclear cells from patients with the hyper-IgD syndrome produce cytokines capable of potent induction of C-reactive protein and serum amyloid A in Hep3B cells. J Immunol 157(1):400–404
Simon A, Drewe E, van der Meer JW et al (2004) Simvastatin treatment for inflammatory attacks of the hyperimmunoglobulinemia D and periodic fever syndrome. Clin Pharmacol Ther 75(5):476–483
Marchetti F, Barbi E, Tommasini A, Oretti C, Ventura A (2004) Inefficacy of etanercept in a child with hyper-IgD syndrome and periodic fever. Clin Exp Rheumatol 22(6):791–792
Bodar EJ, van der Hilst JC, Drenth JP, van der Meer JW, Simon A (2005) Effect of etanercept and anakinra on inflammatory attacks in the hyper-IgD syndrome: introducing a vaccination provocation model. Neth J Med 63(7):260–264
Drenth JP, van Deuren M, van der Ven-Jongekrijg J, Schalkwijk CG, van der Meer JW (1995) Cytokine activation during attacks of the hyperimmunoglobulinemia D and periodic fever syndrome. Blood 85(12):3586–3593
Takada K, Aksentijevich I, Mahadevan V, Dean JA, Kelley RI, Kastner DL (2003) Favorable preliminary experience with etanercept in two patients with the hyperimmunoglobulinemia D and periodic fever syndrome. Arthritis Rheum 48(9):2645–2651
Arkwright PD, McDermott MF, Houten SM et al (2002) Hyper IgD syndrome (HIDS) associated with in vitro evidence of defective monocyte TNFRSF1A shedding and partial response to TNF receptor blockade with etanercept. Clin Exp Immunol 130(3):484–488
Ozen S, Bakkaloglu A, Yilmaz E et al (2003) Mutations in the gene for familial Mediterranean fever: do they predispose to inflammation? J Rheumatol 30(9):2014–2018
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Demirkaya, E., Caglar, M.K., Waterham, H.R. et al. A patient with hyper-IgD syndrome responding to anti-TNF treatment. Clin Rheumatol 26, 1757–1759 (2007). https://doi.org/10.1007/s10067-006-0501-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-006-0501-1